Market Pulse Archives

Jan. 5, 2022, 6:57 a.m. EST

Pfizer, BioNTech to collaborate in developing mRNA-based shingles vaccine

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    BioNTech SE ADR (BNTX)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Pfizer Inc. /zigman2/quotes/202877789/composite PFE +0.50% rose 1.6% in premarket trading Wednesday and BioNTech SE /zigman2/quotes/214419716/composite BNTX +6.88% gained 0.9%, after the drug makers said they will collaborate in developing a potential first mRNA-based shingles vaccine. The companies said they will leverage the antigen technology identified by Pfizer and BioNTech's mRNA platform technology, which were used to develop their COVID-19 vaccine. Clinical trials of the potential shingles vaccine are expected to start in the second half of 2022. Under terms of the collaboration agreement, Pfizer will make upfront payments of $225 million to BioNTech, including a $75 million cash payment and $150 million equity investment, while BioNTech will pay Pfizer $25 million for its antigen technology. BioNTech will be eligible to receive regulatory and sales milestone payments of up to $200 million. Pfizer's stock has rallied 46.6% over the past 12 months and BioNTech shares have soared 158.2%, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.58% has advanced 28.6%.

/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 50.65
+0.25 +0.50%
Volume: 19.87M
May 19, 2022 4:03p
P/E Ratio
11.62
Dividend Yield
3.16%
Market Cap
$284.65 billion
Rev. per Employee
$1.17M
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 167.87
+10.81 +6.88%
Volume: 1.82M
May 19, 2022 4:00p
P/E Ratio
3.52
Dividend Yield
0.91%
Market Cap
$38.17 billion
Rev. per Employee
$7.28M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,900.79
-22.89 -0.58%
Volume: 2.77B
May 19, 2022 4:57p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.